A T Cohen

Summary

Affiliation: King's College London
Country: UK

Publications

  1. Lanitis T, LEIPOLD R, Hamilton M, Rublee D, Quon P, Browne C, et al. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res. 2017;17:74 pubmed publisher
    ....
  2. Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-23 pubmed publisher
    ..Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.). ..
  3. Bauersachs R, Agnelli G, Gitt A, Monreal M, Mismetti P, Willich S, et al. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017;157:181-188 pubmed publisher
    ..This could result in adverse outcomes or suboptimal anticoagulation. Intervention programs to raise awareness amongst physicians may be merited. ..
  4. Wijnberge M, Parmar K, Kesse Adu R, Howard J, Cohen A, Hunt B. The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thromb Res. 2017;158:113-120 pubmed publisher
    ....

Detail Information

Publications4

  1. Lanitis T, LEIPOLD R, Hamilton M, Rublee D, Quon P, Browne C, et al. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res. 2017;17:74 pubmed publisher
    ....
  2. Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-23 pubmed publisher
    ..Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.). ..
  3. Bauersachs R, Agnelli G, Gitt A, Monreal M, Mismetti P, Willich S, et al. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017;157:181-188 pubmed publisher
    ..This could result in adverse outcomes or suboptimal anticoagulation. Intervention programs to raise awareness amongst physicians may be merited. ..
  4. Wijnberge M, Parmar K, Kesse Adu R, Howard J, Cohen A, Hunt B. The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thromb Res. 2017;158:113-120 pubmed publisher
    ....